Picture of Anatara Lifesciences logo

ANR — Anatara Lifesciences Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-8.5%
3m-7%
6m-16.46%
1yr-34.58%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-51.79%
50d MA-5.79%
200d MA-16.27%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)0.52
PEG Ratio (f)0.01
EPS Growth (f)398.4%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value2.48
Price to Tang. Book2.48
Price to Free Cashflown/a
Price to Salesn/a
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-51.09%
Return on Equity-59.7%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Anatara Lifesciences EPS forecast chart

Profile Summary

Anatara Lifesciences Ltd is an Australia-based specialist life sciences company. The Company is focused on developing oral solutions for gastrointestinal diseases in production animals and humans. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation, which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.

Directors

Last Annual
June 30th, 2021
Last Interim
June 30th, 2021
Incorporated
July 15th, 2010
Public Since
October 16th, 2014
No. of Shareholders
860
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
70,238,523

ANR Share Price Performance

FAQ

Or unlock with your email

Or unlock with your email